Inovio Pharmaceuticals Inc (NASDAQ:INO) – Research analysts at Piper Jaffray Companies dropped their FY2019 earnings estimates for shares of Inovio Pharmaceuticals in a research report issued on Tuesday, November 12th, according to Zacks Investment Research. Piper Jaffray Companies analyst C. Raymond now anticipates that the biopharmaceutical company will post earnings of ($1.09) per share for the year, down from their prior estimate of ($0.87). Piper Jaffray Companies also issued estimates for Inovio Pharmaceuticals’ Q4 2019 earnings at ($0.24) EPS, Q3 2020 earnings at ($0.01) EPS, Q4 2020 earnings at ($0.23) EPS, FY2020 earnings at ($0.72) EPS, Q1 2021 earnings at ($0.22) EPS, Q2 2021 earnings at ($0.23) EPS, Q3 2021 earnings at ($0.23) EPS, FY2021 earnings at ($0.94) EPS, FY2022 earnings at ($0.48) EPS and FY2023 earnings at ($0.01) EPS.